 |
|
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region
Do Young Kim, Bao Nguyen Toan, Chee-Kiat Tan, Irsan Hasan, Lyana Setiawan, Ming-Lung Yu, Namiki Izumi, Nguyen Nguyen Huyen, Pierce Kah-Hoe Chow, Rosmawati Mohamed, Stephen Lam Chan, Tawesak Tanwandee, Teng-Yu Lee, Thi Thanh Nguyen Hai, Tian Yang, Woo-Chang Lee, Henry Lik Yuen Chan
Clin Mol Hepatol. 2023;29(2):277-292. Published online 2023 Jan 30 DOI: https://doi.org/10.3350/cmh.2022.0212
|
|
Citations to this article as recorded by
 PIVKA‐II combined with tumor burden score to predict long‐term outcomes of AFP‐negative hepatocellular carcinoma patients after liver resection
Zhan‐cheng Qiu, You‐wei Wu, Wei‐li Qi, Chuan Li
Cancer Medicine.2024;[Epub] CrossRef Emerging role of molecular diagnosis and personalized therapy for hepatocellular carcinoma
Ming-Da Wang, Yong-Kang Diao, Lan-Qing Yao, Zhong-Qi Fan, Ke-Chun Wang, Han Wu, Li-Hui Gu, Jia-Hao Xu, Chao Li, Guo-Yue Lv, Tian Yang
iLIVER.2024; 3(1): 100083. CrossRef Management Consensus Guidelines for Hepatocellular Carcinoma: 2023 Update on Surveillance, Diagnosis, Systemic Treatment, and Posttreatment Monitoring by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
Wei Teng, Hung-Wei Wang, Shi-Ming Lin
Liver Cancer.2024; : 1. CrossRef Development of a Reliable GADSAH Model for Differentiating AFP-negative Hepatic Benign and Malignant Occupying Lesions
Xiaoling Long, Huan Zeng, Yun Zhang, Qiulong Lu, Zhao Cao, Hong Shu
Journal of Hepatocellular Carcinoma.2024; Volume 11: 607. CrossRef What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?
Min Kyung Park, Yoon Jun Kim
Clinical and Molecular Hepatology.2023; 29(2): 332. CrossRef Challenges in translating clinical guidelines into real-life practice for management of hepatocellular carcinoma in Taiwan
San-Chi Chen
Clinical and Molecular Hepatology.2023; 29(2): 352. CrossRef Diagnostic and Prognostic Nomograms for Hepatocellular Carcinoma Based on PIVKA-II and Serum Biomarkers
Shu An, Xiaoxia Zhan, Min Liu, Laisheng Li, Jian Wu
Diagnostics.2023; 13(8): 1442. CrossRef Efficacy and Safety of Transarterial Chemoembolization with a Three-Stage Mixed Chemoembolic Regimen for Large Unresectable Hepatocellular Carcinoma
Yanjie Yang, Nan Du, Jingqin Ma, Zhijie Peng, Bo Zhou, Jiaze Yu, Xin Zhou, Wen Zhang, Zhiping Yan
Journal of Hepatocellular Carcinoma.2023; Volume 10: 1897. CrossRef Role of protein induced by vitamin-K absence-II in transplanted patients with HCC not producing alpha-fetoprotein
Quirino Lai, Takashi Ito, Samuele Iesari, Toru Ikegami, Daniele Nicolini, Zoe Larghi Laureiro, Massimo Rossi, Marco Vivarelli, Tomoharu Yoshizumi, Etsurou Hatano, Jan Lerut
Liver Transplantation.2023;[Epub] CrossRef Attenuation of binuclear hepatocytes in the paracancerous liver tissue is associated with short‐term recurrence of hepatocellular carcinoma post‐radical surgery
Yifan Zhang, Nan Wang, Fengjie Hao, Yongjun Chen, Xiaochun Fei, Junqing Wang
The FASEB Journal.2023;[Epub] CrossRef Validation of combined AFP, AFP-L3, and PIVKA II for diagnosis and monitoring of hepatocellular carcinoma in Chinese patients
Tianying Ren, Xu Hou, Xin Zhang, Dongliang Chen, Juan Li, Yingnan Zhu, Zhiheng Liu, Dawei Yang
Heliyon.2023; 9(11): e21906. CrossRef Protein induced by vitamin K absence or antagonist II: Experience to date and future directions
Libin Dong, Xun Qiu, Fengqiang Gao, Kai Wang, Xiao Xu
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2023; 1878(6): 189016. CrossRef Regular Alpha-Fetoprotein Tests Boost Curative Treatment and Survival for Hepatocellular Carcinoma Patients in an Endemic Area
Joo Hyun Oh, Jonghyun Lee, Eileen L. Yoon, Soung Won Jeong, Soon Sun Kim, Young Eun Chon, Sang Bong Ahn, Dae Won Jun
Cancers.2023; 16(1): 150. CrossRef
|